Continuing to advance the pipeline and remain on-track to engage with the FDA on TP-04 (Papulopustular Rosacea) and TP-05 ...

The FDA has cleared its first light-based therapy for dry age-related macular degeneration—which the agency described as ...

Although both blepharitis and styes affect the eyelids, the two conditions have different symptoms, causes, and treatment options. To help prevent developing a stye or blepharitis, a person can ...

As the first treatment cleared by the FDA for Demodex blepharitis, an eye disease estimated to affect 25 million people in the U.S. alone, Tarsus Pharmaceuticals’ Xdemvy is pitting its might ...

“For years, millions of patients with Demodex blepharitis have struggled with limited, suboptimal treatment options and the frustration of not being able to address the root cause of their ...

“For years, millions of patients with Demodex blepharitis have struggled with limited, suboptimal treatment options and the frustration of not being able to address the root cause of their ...